Ursula Nestle
Expertise in
4
conditions

Ursula Nestle

Freiburg I. Br, 
Freiburg, BW, DE 
Expertise in
4
conditions
Freiburg I. Br, 
Freiburg, BW, DE 
OverviewLocationsClinical Research

Overview

Ursula Nestle practices in Freiburg, Germany. Ms. Nestle is highly rated in 4 conditions, according to our data. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Anal Cancer, and Tissue Biopsy.

Her clinical research consists of co-authoring 138 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Freiburg I. Br, Freiburg, BW, Germany
Other Locations
Binger Str. 173, Ingelheim Am Rhein, RP 55216, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma.
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Radiation, Drug
Study Drugs: Durvalumab, 5-Fluorouracil, Mitomycin C
Study Phase: Phase 2
LungTech Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC: A Phase II Study in Preparation for a Randomized Phase III Trial
LungTech Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC: A Phase II Study in Preparation for a Randomized Phase III Trial
Enrollment Status: Unknown
Publish Date: January 31, 2020
Intervention Type: Radiation
Study Phase: Phase 2
View 1 Less Clinical Trial

138 Total Publications

Neoadjuvant PD-1 and PD-L1 block with chemotherapy in borderline resectable and unresectable stage III NSCLC: paradigm shift or evidence-poor hype?
Neoadjuvant PD-1 and PD-L1 block with chemotherapy in borderline resectable and unresectable stage III NSCLC: paradigm shift or evidence-poor hype?
Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Published: August 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Nestle's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile